Stocktoria
Electromed, Inc. ELMD
Electromed, Inc. (ELMD) earns a Piotroski F-score of 6/9 (mixed financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2025 revenue was $64.0M at a 11.8% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -2.76 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 6/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.643 |
| Retained earnings / assets | 0.394 |
| EBIT / assets | 0.18 |
| Equity / liabilities | 4.079 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| ELMD | Electromed, Inc. | 6/9 | 10.99 | 46.4 | +17% |
| FOCL | EDAP TMS SA | 3/9 | -5.4 | — | +1.6% |
| IRIX | IRIDEX CORP | 4/9 | -8.01 | — | +8.2% |
| CBLL | Ceribell, Inc. | 3/9 | 3.97 | — | +36.1% |
| VASO | VASO Corp | 6/9 | 0.72 | 21.3 | +2.7% |
| STXS | Stereotaxis, Inc. | 4/9 | — | — | +20.3% |
| ECOR | electroCore, Inc. | 4/9 | — | — | +27.2% |
About Electromed, Inc.
Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy, muscular dystrophies, amyotrophic lateral sclerosis, and post-surgical complications; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions. It also provides single patient use SmartVest and SmartVest Wrap products for health care providers in the acute care setting. It markets its products to physicians, health care providers, and directly to patients. Electromed, Inc. was incorporated in 1992 and is headquartered in New Prague, Minnesota.
FAQ
Is ELMD financially healthy?
Electromed, Inc.'s Piotroski F-score is 6/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does ELMD pay a dividend?
No, Electromed, Inc. does not currently pay a dividend.
How profitable is ELMD?
In FY2025, Electromed, Inc. had a net margin of 11.8% and a return on equity of 17.4%.
Is ELMD overvalued or undervalued?
Electromed, Inc. trades at about 50.0× trailing earnings — above its 10-year norm (10-year range 16.5×–43.5×, median 27.0×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for ELMD?
The average Wall-Street price target for Electromed, Inc. is $40.33, about 5.1% below the recent price, from 3 analysts.
Is ELMD a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Electromed, Inc.: a Piotroski F-score of 6/9, an Altman Z″ in the safe zone, a P/E of about 46.4×. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-06-30. Facts plus Stocktoria's own computed scores — not investment advice.